The John Hancock Preferred Income Fund is currently trading at a rare 7% discount to its net asset value (NAV), compared to its historical premium of 4.38%. It offers an attractive dividend yield of 11.21% with a stable payout ratio of $1.32 per share. The fund's 1-year Z-score of -3.86 indicates it is extremely undervalued, presenting a compelling medium-term arbitrage opportunity for investors. However, risks include high leverage and sensitivity to interest rates, though historical trends suggest potential price recovery.
The John Hancock Preferred Income Fund is the subject of this story, with Pluang market data providing context. Of 150 priced US stocks tradable on Pluang, 96 rose and 50 fell today. Notable movers include Gold Fields Limited at USD 36.89 with a 1-day change of +1.51% and Pluang order activity showing 69% Buy, as of Oct 14, 2026 18:43 WIB.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
